All In Biotech

Drug Trial Radar · NCT04505098

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 39,600 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

39,600

Actual

Start

Aug 7, 2020

Primary completion

Dec 15, 2022

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Kaiser PermanenteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Amarin Corporation
First posted
Aug 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).

Conditions

  • Covid19
  • Atherosclerosis
  • Cardiovascular Diseases
  • Upper Respiratory Tract Infections

Interventions

  • Icosapent ethylDrug

    2 g by mouth twice daily for at least 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of confirmed viral URIsTime frame: 0-12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Research

    Oakland, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.